The interview provides an outline for Nutra Pharma’s growth plans over the next eighteen months.
March 14, 2017 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that Stockguru.com will be releasing an interview with Nutra Pharma’s CEO through their website.
"I appreciate the opportunity to be interviewed by Stockguru.com," commented Rik J Deitsch, CEO of Nutra Pharma. “We have been getting an increasing amount of press lately. Last month we were featured on NBC News Miami in a piece that has since been picked up nationally," he continued. "The current interview with Stockguru.com focusses on our OTC pain drugs, Nyloxin and Pet Pain-Away. These are clinically proven, all-natural products that are available today to deal with pain and inflammation in people and their pets. The interview also outlines the future of the Company’s drug platform, especially the opportunity with our Multiple Sclerosis drug, RPI-78M. This brief interview nicely lays out the current, mid-term and long-term goals of the Company," he concluded.
The full interview is available at: https://stockguru.com/nutra-pharma-ceo-rik-deitsch-interview
According to their website, Stockguru.com is an independent company that features public company alerts that are published three times daily to members. The interview with Rik Deitsch was conducted by Stockguru.com’s publisher, John Pentony.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The interview by Stockguru.com should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.